Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Patent
1997-11-21
2000-11-07
Bui, Phuong T.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
424 9371, 424 855, 424 857, 424 852, 424 854, 4241441, 424577, 424578, 435325, 435375, A61K 3528, C12N 508
Patent
active
06143292&
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to a methods for eradicating tumor cells that remain viable in a patient following allogeneic stem cell transplantation. More particularly, this invention relates to use of allogeneic lymphocytes for eradication of solid tumor cells following allogeneic stem cell transplantation. The invention also relates specifically to use of allogeneic activated donor lymphocytes for treatment of cancer patients, including relapsing patients.
BACKGROUND OF THE INVENTION
Patients suffering from malignant hematological disorders such as leukemia or lymphoma may, under appropriate circumstances, be administered autologous or allogeneic bone marrow transplants as part of a therapeutic regimen. Such transplants also can be useful in conjunction with therapy of non-hematological malignancies such as breast carcinomas or other solid tumors. Bone marrow transplantation makes it possible to administer to patients with resistant disease high, "supra-lethal," combinations of chemotherapy and/or radiation, ignoring the irreversible toxicity of such therapeutic combinations on the normal bone marrow compartment. Nevertheless, such "debulking" of a patient's tumor can leave a fraction of residual malignant cells that may lead to disease relapse.
Several lines of evidence suggest that a significant proportion of the beneficial effect of allogeneic bone marrow transplantation (i.e., bone marrow transplantation from an individual not genetically identical to the host patient) stems from cell-mediated interactions of immune cells of donor origin against residual tumor cells in the host that have escaped the chemoradiotherapy debulking regimen. Following allogeneic bone marrow transplantation (Allo-BMT), the incidence of relapse is significantly lower in leukemia patients with clinical manifestations of acute or chronic graft versus host disease (GVHD), as compared with patients with no GVHD, indicating that immune-mediated allogeneic interactions of immunocompetent cells of donor origin against the host can be accompanied by graft vs. leukemia (GVL) effects.
Higher relapse rates seem to occur in patients undergoing Allo-BMT with T-lymphocyte depletion for prevention of GVHD, compared to recipients of non-T-cell depleted marrow allografts, regardless of the severity of GVHD. Likewise, relapse rates in patients with acute leukemia or chronic myelogenous leukemia reconstituted by bone marrow grafts obtained from an identical twin (syngeneic grafts) are significantly higher than in those reconstituted by bone marrow cells obtained from an HLA-identical but non-syngeneic sibling. Similarly, relapse rates following transplantation of the patient's own (autologous) marrow, even following adequate purging in vitro for elimination of residual leukemia cells, are significantly higher than following Allo-BMT.
Recent studies by several groups have demonstrated that chronic myelogenous leukemia (CML) patients who relapse following Allo-BMT can be treated successfully by infusion of resting (i.e., unactivated by in vitro treatment with T-cell activators such as cytokines) HLA-matched leukocytes from the Allo-BMT donor in order to achieve a second remission. Slavin et al., Blood 72 (Suppl. 1): 407a (1988); Kolb et al., Blood 76:2462 (1990); Baer et al., J. Clin. Oncology 11:513 (1993); Jiang et al., Bone Marrow Transpl. 11:133 (1993); Drobyski et al., Blood 82:2310 (1993); Antin, Blood 82:2273 (1993); Porter et al., N. Engl. J. Med. 330:100-06 (1994).
The therapeutic effects of the infused leukocytes are mediated by potentiation of GVL effects, induced following Allo-BMT, by immunocompetent donor T cells that are not tolerant to the malignant hematopoietic cells. Slavin et al., Blood 72 (Suppl. 1): 407a (1988); Slavin et al., Bone Marrow Transpl. 6:155-61 (1990); Kolb et al., Blood 76:2462 (1990); Baer et al., J. Clin. Oncology 11:513 (1993); Jiang et al., Bone Marrow Transpl. 11:133 (1993); Drobyski et al., Blood 82:2310 (1993); Antin, Blood 82:2273 (1993); Porter et al., N. Engl. J. Med. 330:100-06 (
REFERENCES:
Slavin et al., Leukemia 6:164-166 (1992).
Slavin et al., Bone Marrow Transplant. 12:S54-S56 (1993).
Slavin et al., 19th Annual Meeting of the EBMT and 9th Meeting of the Nurses Group, Abstracts, MMV Medinzin Verlag GmbH, Munich, ISBN 3-8208-1199-0; 48 (Abstract 1601) (1993).
Slavin et al., Blood 82:423a (Abstract 1677) (1993).
Slavin et al., Bone Marrow Transplant. 4:80-81 (1988).
Naparstek et al., Experimental Hematology 21:1061 (Abstract 189) (1993).
Weiss et al., Cancer Immunol. Immunother. 31:236-242 (1990).
Slavin et al., Haematology and Blood Transfusion 33:36-40 (1990).
J. Antin, Blood 82:2273-2277 (1993).
Bar et al., J. Clin. Oncology 11:513-519 (1993).
Collins et al., Blood 82:417a (Abstract 1652) (1993).
De Witte et al., Exp. Hematol. 20:723 (Abstract 71) (1992).
Drobyski et al., Bone Marrow Transplantation 10:301-304 (1992).
Drobyski et al., Blood 82:2310-2318 (1993).
Frassoni et al., Exp. Hematol. 20:712 (Abstract 30) (1992).
Helg et al., Bone Marrow Transplantation 12:125-129 (1993).
Hertenstein et al., Transplantation 56:1114-1118 (1993).
Jiang et al., Bone Marrow Transplantation 11:133-138 (1993).
Johnson et al., Bone Marrow Transplantation 11:329-336 (1993).
Kolb et al., 19th Annual Meeting of EBMT, Eur. Group Bone Marrow Transplant (Abstract 1605) (1993).
Kolb et al., Blood 82:214a (Abstract 840) (1993).
Leber et al., Bone Marrow Transplantation 12:405-407 (1993).
Novotny et al., Chronic Myeloid Leukemia Second International Conference (Abstract 277) (1992).
Porter et al., N. Engl. J. Med. 330:100-106 (1994).
van Rhee et al., Blood 82:416a (Abstract 1650) (1993).
van Rhee et al., Blood 83:3377-3383 (1994).
Szer et al., Bone Marrow Transplantation 11:109-111 (1993).
Slavin et al., Cancer Investigation 10:221-227 (1992).
Delain et al., Leukemia 8:642-647 (1994).
Marmont, Leukemia and Lymphoma, 11:221-226 (1992).
Ackerstein et al., Blood 974a (Abstract 3886) (1995).
Slavin et al., Blood 87:2195-2204 (1996).
Buzyn-Veil, British Journal of Haematology 92:423-425 (1996).
Giralt et al., Blood 8:4337-4343 (1995).
Baxter International Inc.
Bui Phuong T.
Hadasit Medical Research Services and Development Ltd.
LandOfFree
Allogeneic cell therapy for cancer following allogeneic stem cel does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Allogeneic cell therapy for cancer following allogeneic stem cel, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Allogeneic cell therapy for cancer following allogeneic stem cel will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1638082